California-based Amgen recently obtained U.S. Food and Drug Administration (FDA) acceptance of its Biologics License Application (BLA) for Aimovig (erenumab), a product developed specifically to help victims of frequent migraine headaches. Read More »

To better tend babies in the nation’s neonatal intensive care units, the first magnetic resonance imaging (MRI) device designed for newborns recently garnered U.S. Food and Drug Administration approval following thorough safety confirmation. Read More »

Pharmaceutical provider AmerisourceBergen recently unveiled the DIR Fee Estimator, its newest tool in conjunction with its nationwide Good Neighbor Pharmacy network, to streamline transactions between provider networks and pharmacy benefit managers by providing cost estimate ranges. Read More »

Sanofi and Regeneron Pharmaceuticals Inc. recently announced that Kevzara (sarilumab), a treatment for adult patients with moderately to severely active rheumatoid arthritis who have not responded well to one or more disease modifying antirheumatic drugs, has been approved by the U.S. Food and Drug Administration. Read More »

Therigy, a company that pioneered patient-focused specialty therapy management, recently announced a strategic partnership with EPI-Q Inc. to expand research on specialty pharmacy outcomes. Read More »

Amgen and UCB recently announced that their Evenity study, which analyzed the drug as a treatment for postmenopausal women with osteoporosis, met both primary endpoints and the secondary endpoint. Read More »

Biologics Inc., a McKesson Specialty Health oncology pharmacy services company, has been chosen by AstraZeneca to distribute Imfinzi. Read More »

Xynomic Pharma's has initiated a strategic partnership with the University of California San Francisco for a PAX Study – a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat, as opposed to Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma. Read More »

Sun Pharmaceutical Industries Ltd.'s Biologics License Application for tildrakizumab has been accepted by the U.S. Food and Drug Administration. Read More »

Pfizer Inc.'s proposed epoetin alfa biosimilar has been recommended for approval across all indications by the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee. Read More »

EMD Serono, the biopharmaceutical business of Merck KGaA in the United States and Canada, recently showcased 14 presentations at the 31st Annual Meeting of the Consortium of Multiple Sclerosis Centers, including eight sets of data on Cladribine Tablet, a treatment for patients with relapsing multiple sclerosis. Read More »

Novartis' Zykadia, a treatment for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, has been approved for expanded use by the U.S. Food and Drug Administration. Read More »

Optum, UnitedHealth Group’s health services business, and Merck recently announced collaboration on developing and simulating the performance of contractual reimbursement models that align payment for prescription drugs with patient health outcomes. Read More »

Agricultural technology firm Arcadia Biosciences Inc. has successfully attained an Early Food Safety Evaluation from the U.S. Food and Drug Administration determining that its functional protein product is safe for humans and animals. Read More »

Test detects five most commonly misused and abused prescription drugs; five-minute results will facilitate rapid interventions in prescription drug abuse. Read More »

The last patient in the Phase II BEKINDA (RBH-102) study has completed the treatment and follow-up, RedHill Biopharma Ltd. announced on Monday. Read More »

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt has written directly to U.S. Food and Drug Administration Commissioner Scott Gottlieb to offer the association’s concise solution for fast-tracking “common-sense” improvements to the nation’s opioid abuse policy. Read More »

Amgen of Thousand Oaks, California and Array BioPharma of Boulder, Colorado recently created a cooperative contract to develop innovative drugs aimed at combating autoimmune disorders after Array’s breakthrough discovery of certain target and lead inhibitors. Read More »

Launching a four-year research program to develop diabetes and obesity treatments, PreveCeutical Medical Inc. of Vancouver, British Columbia recently signed an agreement with UniQuest Pty Ltd. of the University of Queensland in Australia. Read More »

Chronic hepatitis C virus (HCV) patients have a new treatment option with the approval of Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) by the U.S. Food and Drug Administration. Read More »